Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as...
ASCO’s Clinical Cancer Advances report, our 14th edition, examines the most transformative research of the past year and offers our vision for future research priorities.
Predictive analytics, complex treatment pathways, tele-oncology, and more: Dr. Robert M. Daly identifies five trends that are poised to disrupt oncology practice in the coming year.
GLOBOCAN 2018 indicates a significant global increase in the numbers, incidence, and mortality rates, albeit significant differences in mortality amongst countries of different economic levels.
ASCO's nearly 45,000 members practice in more than 150 countries, and continued progress against cancer will require every one of us, writes ASCO CMO Dr. Richard L. Schilsky.
